SlideShare una empresa de Scribd logo
1 de 70
Descargar para leer sin conexión
Updates on Acute respiratory distress syndrome
Hamdi Turkey - chest physician
I hope you are still awake at the end
of this lecture !
Case presentation
A 35 year old male patient was
r u s h e d i n t o t h e E R
complaining of SOB for the
past 3 days, he has fever,
Tachypnea, pulse 110 bpm,BP
80/50 mmHg, pallor and
cyanosed, normal JVP, normal
S1 and S2 with no added
sounds, on chest auscultation
there was bilateral diffuse
crackles.
SpO2 on room air was 60, ABG
: PaO2= 40, Pco2= 40, pH=7.3
What's the diagnosis?
Learning Objectives
To know the new definition of ARDS
To understand the pathology and pathophysiology of ARDS
To devise a ventilation strategy for these patients.
To introduce the concept of ventilator induced lung injury
To address adjunct and rescue therapy for patients with
resistant hypoxemia.
History
I n 1 9 6 7 A s h b a u g h a n d
colleagues published a case
series in the Lancet which
described a clinical syndrome,
which they (later) termed “Adult
R e s p i r a t o r y D i s t r e s s
Syndrome” (ARDS). The 12
patients involved complained of
acute respiratory distress,
cyanosis refractory to oxygen
t h e r a py, d e c r e a s e d l u n g
c o m p l i a n c e a n d d i f f u s e
pulmonary infiltrates on chest
x-ray.
Trauma doctors involved in treating victims of war had
long been familiar with this syndrome, which came to be
known as “wet lung”, “shock lung” or “Da-nang lung”.

This problem had been identified during World War II but
with the advent of advanced trauma (M.A.S.H. units
during the Vietnam war) the prevalence of this form of
respiratory failure was truly recognized.

Over the past 30 or so years, this syndrome has come to
be one of the central problems of intensive care: lung
injury arising from a variety of different etiologies, each
characterized by bilateral diffuse infiltrates on x-ray,
hypoxemia, and non-cardiogenic pulmonary edema.
History
In 1988, an expanded definition was
proposed that quantified the
physiologic respiratory impairment
through the use of a four-point lung-
injury scoring system that was based
on:

level of positive end-expiratory
pressure
ratio of the partial pressure of
arterial oxygen to the fraction of
inspired oxygen
static lung compliance
degree of infiltration evident on
chest radiographs.
History
Before research into the pathogenesis and
treatment of this syndrome could proceed, it was
necessary to formulate a clear definition of the
syndrome. Such a definition was developed in 1994
by the American-European Consensus Conference
(AECC) on acute respiratory distress syndrome
(ARDS).
The term “acute respiratory distress syndrome”
was used instead of “adult respiratory distress
syndrome” because the syndrome occurs in both
adults and children.
History
The Berlin Definition of ARDS
(published in 2012) has replaced the
American-European Consensus
Conference’s definition of ARDS
(published in 1994). However, it should
be recognized that most evidence is
based upon prior definitions.
History
Other terms
Shock lung
Pump lung
Traumatic wet lung
Post traumatic
atelectasis
Adult hyaline
membrane disease
Progressive respiratory
distress
Acute respiratory
insufficiency syndrome
Haemorrhagic
atelectasis
Hypoxic
hyperventilation
Postperfusion lung
Oxygen toxicity lung
Wet lung
White lung
Transplant lung
Da Nang lung
Diffuse alveolar injury
Acute diffuse lung
injury
Noncardiogenic
pulmonary edema.
Progressive
pulmonary
consolidation
AECC Past definition of ARDS
ARDS was defined as:
the acute onset of respiratory failure, bilateral
infiltrates on chest radiograph, hypoxemia as
defined by a PaO2/FiO2 ratio ≤200 mmHg, and no
evidence of left atrial hypertension or a pulmonary
capillary pressure <18 mmHg (if measured) to rule
out cardiogenic edema. In addition, Acute Lung
Injury (ALI), the less severe form of acute
respiratory failure, was different from ARDS only
for the degree of hypoxemia, in fact it was defined
by a 200 < PaO2/FiO2 ≤300 mmHg.
The 1994 AECC definition
became globally accepted, but
had limitations
The current definition is the
‘Berlin Definition’ published
in 2013, which was created by
a consensus panel of experts
convened in 2011 (an initiative
of the European Society of
Intensive Care Medicine
endorsed by the American
Thoracic Society and the
Society of Critical Care
Medicine)
AECC Past definition of ARDS
ARDS BERLIN DEFINITION
ARDS is an acute diffuse, inflammatory
lung injury, leading to increased pulmonary
vascular permeability, increased lung
weight, and loss of aerated lung tissue…
[ w i t h ] h y p o x e m i a a n d b i l a t e r a l
radiographic opacities, associated with
increased venous admixture, increased
physiological dead space and decreased
lung compliance.
The goal of developing the Berlin definition was to try
and improve feasibility, reliability, face and predictive
validity
ARDS BERLIN DEFINITION
Timing of acute onset
The timing of acute onset of respiratory
failure to make diagnosis of ARDS is clearly
defined in Berlin definition.
It defines the exposure to a known risk factor
or worsening of the respiratory symptoms
within one week.
It is important to identify risk factors that
explain the context of acute respiratory
failure arised from
Oxygenation
In the Berlin definition, there is no use of the term
Acute Lung Injury (ALI).
The committee felt that this term was used
inappropriately in many contexts and hence was
not helpful.
In the Berlin definition, ARDS was classified as
mild, moderate and severe according to the value
of PaO2/FiO2 ratio. Importantly, the PaO2/FiO2
ratio value is considered only with a CPAP or PEEP
value of at least 5 cmH2O.
The chest radiograph is characterized by bilateral
opacities involving at least 3 quadrants that are not
fully explained by pleural effusions, atelectasis and
nodules.
In the absence of known risk factors, a cardiogenic
origin of edema is to be excluded by objective
evaluation of cardiac function with echocardiography.
Consequently, the wedge pressure measurement was
abandoned because ARDS may coexist with
hydrostatic edema caused by fluid overload or cardiac
failure.
Chest X-ray
Key components
acute, meaning onset over 1 week or less
bilateral opacities consistent with pulmonary edema
must be present but may be detected on CT or chest
radiograph
PF ratio <300mmHg with a minimum of 5 cmH20 PEEP
(or CPAP)
must not be fully explained by cardiac failure or fluid
overload,” in the physician’s best estimation using
available information — an “objective assessment“ (e.g.
echocardiogram) should be performed in most cases if
there is no clear cause such as trauma or sepsis.
Severity
*on PEEP 5+; **observed in cohort
ARDS is categorized as being mild, moderate, or severe:
ARDS Severity PaO2/FiO2* Mortality**
Mild 200 – 300 27%
Moderate 100 – 200 32%
Severe < 100 45%
Changes from the 1994 AECC
definition
the term acute lung injury was abandoned
measurement of the PaO2/FIO2 ratio was changed to
require a specific minimum amount of PEEP
3 categories of ARDS were proposed (mild, moderate, and
severe) based on the PaO2/FIO2 ratio
Radiographic criteria were changed to improve interrater
reliability
PCWP criterion was removed and additional clarity was
added to improve the ability to exclude cardiac causes of
bilateral infiltrates
1994 AECC
DEFINITION
Now
obsolete
Shortcoming of the AECC
definition
acute is ill defined
PF ratio can be manipulated by adjusting PEEP
CXR interpretation is unreliable
PACs are rarely used
PCWP may oscillate above and below the cut-off and
may be elevated for reasons other than heart failure
ALI was used inconsistently, just PF ratio 200 to 300,
or all patients <300 including ARDS?
Incidence and outcome
■ 20-75 per 100,000
■ 30% mortality
■ Recovery may take 6-12 months
■ Residual:
Restriction
	 	 	 Obstruction
	 	 	 Gas- Exchange Abnormalities
	 	 	 Reduced Quality of Life
Direct
pneumonia
aspiration of gastric
contents
lung contusion
fat embolism
Amniotic fluid
embolism
near drowning
inhalational injury
reperfusion injury
non-pulmonary sepsis 
multiple trauma 
massive transfusion 
pancreatitits 
Salicylate or narcotic
overdose
cardiopulmonary bypass
Indirect
Risk factors
Cardiogenic Vs non cardiogenic
pulmonary edema
Cardiogenic Non-Cardiogenic
Patchy infiltrates in
bases
Effusions
Kerley B lines
Cardiomegaly
Pulmonary vascular
redistribution 
Excess fluid in alveoli
Homogenous fluffy
shadows 
No effusion 
No Kerley B lines
No cardiomegaly
No pulmonary vascular
redistribution
Protein, inflammatory cells,
fluid
Cardiogenic Non-Cardiogenic
Cardiogenic Non-Cardiogenic
Pathophysiology
Classical phases
Injury
Exudative – alveolar capillary membrane disruption with
inflammatory cell infiltrate and high protein exudate to form
hyaline membranes
Proliferative – proliferation of abnormal Type II alveoli cells and
inflammatory cells
Fibrotic – infiltration with fibroblasts which replace alveoli and
alveolar ducts with fibrosis
Resolution – slow and incomplete repair and restoration of
architecture
Pathophysiology
Based on the histological appearance -
Exudative phase (0-4 days)
• Alveolar and interstitial edema
• Capillary congestion
• Destruction of type I alveolar cells
• Early hyaline membrane formation
Proliferative Phase (3-10 days)
• Increased type II alveolar cells
• Cellular infiltration of alveolar septum
• Organisation of hyaline membranes
Fibrotic Phase (>10 days)
• Fibrosis of hyaline membranes and alveolar septum
• Alveolar duct fibrosis
Findings on Light Microscopy and Electron Microscopy
during the Acute Phase (Panels A and D) and the Fibrosing-
Alveolitis Phase (Panels B, C, and E) of Acute Respiratory
Distress Syndrome.
Pathophysiology
Mechanisms in early phase -
• Release of inflammatory cytokines – TNF alpha, IL-
1,6,8
• Failure of alveolar edema clearance, epithelial and
endothelial damage
• Increased permeability of alveolo – capillary membrane
• Neutrophil migration and oxidative stress
• Procoagulant shift – fibrin deposition
• Surfactant dysfunction

Mechanism in late (repair) phase –
• Fibroproliferation -TGF beta, MMPs, thombospondin,
plasmin, ROS
• Remodelling - matrix and cell surface proteoglycans,
MMP, imbalance of coagulation and fibrinolysis.
Pathophysiology
Complex interplay
pulmonary oedema from damage to the alveolocapillary barrier
inflammatory infiltrates
surfactant dysfunction
It is essential to understand that although ALI is a diffuse
process, it is also a heterogeneous process, and not all
lung units are affected equally: normal and diseased
tissue may exist side-by-side.
Effects
hypoxaemia (V/Q mismatch, impaired hypoxic pulmonar y
vasoconstriction)
increase in dependent densities (surfactant dysfunction, alveolar
instabilities)
decreased compliance (surfactant dysfunction, decreased lung volume,
fibrosis)
collapse/consolidation (increased compression of dependent lung)
increased minute ventilation (increased in alveolar dead space)
increased work of breathing (increased elastance, increased minute
volume requirement)
pulmonary hypertension (vasoconstriction, microvascular thrombi,
fibrosis, PEEP)
Host factors increasing the risk of
ARDS
Clinical variables found to be associated with an increased
risk of ARDS









Diabetes mellitus decreases the risk of ALI.
chronic alcohol abuse
hypoproteinemia
advanced age,
increased severity,and extent of injury or illness as
measured by injury severity score (ISS) or
APACHEscore
hyper-transfusion of blood products
cigarette smoking.
Causative factors in ARDS
Primary injury Host response
Consequences of
therapy
Clinical features
Symptoms
Acute respiratory distress syndrome (ARDS) is characterized by the
development of acute dyspnea and hypoxemia within hours to days of an
inciting event, such as trauma, sepsis, drug overdose, massive transfusion, acute
pancreatitis, or aspiration. In many cases, the inciting event is obvious, but, in
others (eg, drug overdose), it may be harder to identify.

Patients developing ARDS are critically ill, often with multisystem organ
failure, and they may not be capable of providing historical information.
Typically, the illness develops within 12-48 hours after the inciting event,
although, in rare instances, it may take up to a few days.

With the onset of lung injury, patients initially note dyspnea with exertion. This
rapidly progresses to severe dyspnea at rest, tachypnea, anxiety, agitation, and
the need for increasingly high concentrations of inspired oxygen.
Physical findings
Physical findings often are nonspecific and include tachypnea, tachycardia, and the
need for a high fraction of inspired oxygen (FIO2) to maintain oxygen saturation.
The patient may be febrile or hypothermic. Because ARDS often occurs in the
context of sepsis, associated hypotension and peripheral vasoconstriction with cold
extremities may be present. Cyanosis of the lips and nail beds may occur.

Examination of the lungs may reveal bilateral rales. Rales may not be present
despite widespread involvement. Because the patient is often intubated and
mechanically ventilated, decreased breath sounds over 1 lung may indicate a
pneumothorax or endotracheal tube down the right main bronchus.

Manifestations of the underlying cause (eg, acute abdominal findings in the case of
ARDS caused by pancreatitis) are present.
Symptoms
and signs
that
suggest a
cause of
ARDS
Laboratory investigations
Routine blood counts
RFT
LFT
Blood culture
BNP
ABG
BAL
ECHO
Chest CT scan
PCWP
Classic Chest X Ray of a patient with ARDS, although the
lung injury appears diffuse, when you look at the CT scan
of the same patient on the right you can see that the lower
lobes are densely consolidated and the upper lobes
relatively spared. Nevertheless, this patient was severely
hypoxic, and responded well to prone positioning.
Management
Therapy- goals
Treatment of the underlying cause
Cardio-pulmonary support
Specific therapy targeted at lung therapy 
Supportive therapy
Diagnosis and appropriate treatment of the underlying cause
to minimise physiological impact of cause (drain collection,
antibiotics, resuscitate, splint fractures)
Nutritional support 
Standard ICU prophylaxis
Stress ulcer prophylaxis
Prevention of nosocomial infections
CVP monitoring with CV line with appropriate fluid therapy
General measures
Goal of
management
of a patient
with ARDS
Treatable
inciting
causes of
ARDS
Lung protective strategy in ARDS
A myth or a fact!
Mechanical ventilation
Therapy- mechanical ventilation
The Problem: Ventilator- Induced Lung Injury
■ High volumes and pressures: Stress
( barotrauma)
■ Overdistension & Alveolar Cracking
( volumtrauma)
■ Cyclic Opening and closing of atelectatic
alveoli ( atelectrauma)

Cause increased permeability and alveolar
damage
The Problem: Oxygen Toxicity
■ Free Radicals
■ Oxygen Washout and De-Recruitment

High FiO2 can lead to further alveolar
damage
Therapy- mechanical ventilation
■ Intubation almost always necessary
■ In past, goal was to normalize pH,
PaCO2, PaO2
■ High volumes and pressures were used
■ Worse outcomes
Therapy- mechanical ventilation
Lung protective strategy
	 Amato et al. 1998, Effects of a protective-
ventilation strategy on mortality in the acute
respiratory distress syndrome. N. Engl. J. Med.
338:347-54
■ 53 pts with early ARDS
■ Compared “conventional” ventilation of 12ml/kg
to “protective” 6ml/kg
■ Low PEEP. PaCO2 35-38
■ Improved survival at 28 days
■ Higher percentage of ventilator weaning
■ Less barotrauma
The Acute Respiratory Distress Network. 2000.
Ventilation with lower tidal volumes as compared with
traditional tidal volumes for acute lung injury and the acute
respiratory distress syndrome. N. Engl. J. Med. 342:1301-8
■ Larger Trial. 861 patients
■ Compared 12 ml/kg vs. 6ml/kg ventilation.
■ Plateau pressures 50 cm H2O vs. 30 cm H2O.
■ Trial ended early:
■39.8% mortality vs. 31% mortality

THIS HAS CHANGED CLINICAL PRACTICE
Lung protective strategy
Mechanical ventilation
ARDS Network protective lung ventilation strategy (from the
ARMA study)
controlled ventilation
TV 6mL/kg
avoid overstretch (volutrauma) and inadequate recruitment
(atelectrauma)
PEEP 5-15
Plateau pressure <30 cmH20 (higher than this contributes
to VILI from overstretching and hyperinflation of the
functional ‘baby lung’)
mode of ventilation: generally no difference
PCV tends to be used c/o plateau pressure
approximates peak pressure, with VC plateau
pressure needs to be measured
no role for inverse ratio ventilation (I:E ratio > 1) ->
increased mean airway pressure + haemodynamic
instability + regional hyperinflation
oxygenation target: SpO2 88-95%, PaO2 > 55-80 mmHg
carbon dioxide target: ARDSnet aimed for a normal
CO2 -> but lung is exposed to repeated tidal stretch,
ideally hypercapnia should be minimised but there
isn’t compelling data to suggest it is harmful unless
there is an obvious reason (raised ICP, pregnancy).
Ventilator
strategy
in ARDS
Ventilator settings
for lung protection
Complications
related to MV
Other techniques to improve oxygenation
prone posture: improves oxygenation and mortality in
severe ARDS
recruitment manoeuvres (e.g. PEEP 30-40cmH2O held
for 30 seconds or staircase recruitment manouvre) ->
can improve oxygenation but controversial, not
everyone responds
inhaled iNO: optimisation of V/Q mismatch,
1-60ppm, on 40-70% will respond, monitor for metHb
inhaled prostacycline (PGI2): optimisation of V/Q
mis-match, 1-50ng/kg/min, as effective as iNO
Pharmacological therapy
surfactant replacement therapy: theoretically good, improves
oxygenation but no improvement in mortality, problems with
distribution to alveoli
Diuretics : liberal vs conservative strategy
glucocorticoids: improvement in ventilator free days and shock,
no improvement in mortality and increase in weakness
ketoconazole: antifungal that inhibits thromboxane synthase and
5-lipooxygenase -> early data but not confirmed.
others: cytokine antagonism, NSAIDS, scavengers of O2 radicals,
lisofylline -> no success

Seek and treat underlying causes and complications
A randomized, clinical trial determined that simvastatin, a
hydroxymethylglutaryl-coenzyme A reductase inhibitor, improved oxygenation
and respiratory mechanics in patients with ALI. Further studies are needed, but
treatment with simvastatin appears safe and may be associated with improved
organ dysfunction in patients with ALI.

Statins
Pharmacological therapy
Activated protein C
Drotrecogin alfa was withdrawn from the worldwide market October 25, 2011. In
the Recombinant Human Activated Protein C Worldwide Evaluation in Severe
Sepsis (PROWESS)-SHOCK clinical trial, drotrecogin alfa failed to demonstrate a
statistically significant reduction in 28-day all-cause mortality in patients with
severe sepsis and septic shock. Trial results observed a 28-day all-cause mortality
rate of 26.4% in patients treated with activated drotrecogin alfa compared with
24.2% in the placebo group of the study.
In these critically ill patients, pay careful
attention to early recognition of potential
complications in the intensive care unit (ICU),
including pneumothorax, IV line infections, skin
breakdown, inadequate nutrition, arterial
occlusion at the site of intra-arterial monitoring
devices, DVT and pulmonary embolism (PE),
retroperitoneal hemorrhage, gastrointestinal
(GI) hemorrhage, erroneous placement of lines
and tubes, and the development of muscle
weakness.
Prognosis
pulmonary function returns to normal at 6-12 months in
survivors
occasionally patient have severe restrictive lung disease
although this is the case, many patient have a severe
reduction and pulmonary QOL -> depression, anxiety
and PTSD are common
patient often have cognitive impairment -> these
correlate with the period and severity of hypoxia
Thank you

Más contenido relacionado

La actualidad más candente

Acute Respirtaory Distress Syndrome
Acute Respirtaory Distress SyndromeAcute Respirtaory Distress Syndrome
Acute Respirtaory Distress SyndromeDavid Hersey
 
Ards 2018
Ards 2018Ards 2018
Ards 2018imran80
 
pulmonary embolism
pulmonary embolismpulmonary embolism
pulmonary embolismaravazhi
 
ACUTE RESPIRATORY DISTRESS SYNDROME. (ARDS)
ACUTE RESPIRATORY DISTRESS SYNDROME. (ARDS) ACUTE RESPIRATORY DISTRESS SYNDROME. (ARDS)
ACUTE RESPIRATORY DISTRESS SYNDROME. (ARDS) Adel Hamada
 
Approach to a patient of dyspnea
Approach to a patient of dyspneaApproach to a patient of dyspnea
Approach to a patient of dyspneaDr Rakesh Solanki
 
Respiratory Complication Of Rheumatic Disease
Respiratory Complication Of Rheumatic DiseaseRespiratory Complication Of Rheumatic Disease
Respiratory Complication Of Rheumatic Diseasedrmomusa
 
Pulmonary embolism
Pulmonary embolism Pulmonary embolism
Pulmonary embolism Zahra Khan
 
Acute Respiratory Distress Syndrome
Acute Respiratory Distress SyndromeAcute Respiratory Distress Syndrome
Acute Respiratory Distress SyndromeRikin Hasnani
 
Hepato Pulmonary syndrome - Dr.Tinku Joseph
Hepato Pulmonary syndrome - Dr.Tinku JosephHepato Pulmonary syndrome - Dr.Tinku Joseph
Hepato Pulmonary syndrome - Dr.Tinku JosephDr.Tinku Joseph
 
Acute respiratory distress syndrome (ards)
Acute respiratory distress syndrome (ards)Acute respiratory distress syndrome (ards)
Acute respiratory distress syndrome (ards)Sarath Menon
 
Pulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku josephPulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku josephDr.Tinku Joseph
 
Respiratory failure
Respiratory failureRespiratory failure
Respiratory failureAdel Hamada
 
Pulmonary hypertension
Pulmonary hypertensionPulmonary hypertension
Pulmonary hypertensionAbhay Mange
 

La actualidad más candente (20)

Acute Respirtaory Distress Syndrome
Acute Respirtaory Distress SyndromeAcute Respirtaory Distress Syndrome
Acute Respirtaory Distress Syndrome
 
Ards hoover
Ards   hooverArds   hoover
Ards hoover
 
Ards 2018
Ards 2018Ards 2018
Ards 2018
 
pulmonary embolism
pulmonary embolismpulmonary embolism
pulmonary embolism
 
ACUTE RESPIRATORY DISTRESS SYNDROME. (ARDS)
ACUTE RESPIRATORY DISTRESS SYNDROME. (ARDS) ACUTE RESPIRATORY DISTRESS SYNDROME. (ARDS)
ACUTE RESPIRATORY DISTRESS SYNDROME. (ARDS)
 
Approach to pleural effusion
Approach to pleural effusionApproach to pleural effusion
Approach to pleural effusion
 
Approach to a patient of dyspnea
Approach to a patient of dyspneaApproach to a patient of dyspnea
Approach to a patient of dyspnea
 
Respiratory failure
Respiratory failureRespiratory failure
Respiratory failure
 
Respiratory Complication Of Rheumatic Disease
Respiratory Complication Of Rheumatic DiseaseRespiratory Complication Of Rheumatic Disease
Respiratory Complication Of Rheumatic Disease
 
Pulmonary embolism
Pulmonary embolism Pulmonary embolism
Pulmonary embolism
 
dyspnea approach
dyspnea approachdyspnea approach
dyspnea approach
 
A a gradient fin
A a gradient finA a gradient fin
A a gradient fin
 
Acute Respiratory Distress Syndrome
Acute Respiratory Distress SyndromeAcute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome
 
Hepato Pulmonary syndrome - Dr.Tinku Joseph
Hepato Pulmonary syndrome - Dr.Tinku JosephHepato Pulmonary syndrome - Dr.Tinku Joseph
Hepato Pulmonary syndrome - Dr.Tinku Joseph
 
Acute respiratory distress syndrome (ards)
Acute respiratory distress syndrome (ards)Acute respiratory distress syndrome (ards)
Acute respiratory distress syndrome (ards)
 
Pulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku josephPulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku joseph
 
Pulmonary edema
Pulmonary edemaPulmonary edema
Pulmonary edema
 
Respiratory failure
Respiratory failureRespiratory failure
Respiratory failure
 
Pulmonary hypertension
Pulmonary hypertensionPulmonary hypertension
Pulmonary hypertension
 
Ards2
Ards2Ards2
Ards2
 

Similar a Updates on Acute respiratory distress syndrome

ACUTE RESPIRATORY DISTRESS SYNDROME
ACUTE RESPIRATORY DISTRESS SYNDROMEACUTE RESPIRATORY DISTRESS SYNDROME
ACUTE RESPIRATORY DISTRESS SYNDROMEAbhinovKandur
 
Ards level 3 lecture
Ards level 3 lectureArds level 3 lecture
Ards level 3 lectureEric Mugambi
 
Dr. Radhey Shyam (presentation)
Dr. Radhey Shyam (presentation)Dr. Radhey Shyam (presentation)
Dr. Radhey Shyam (presentation)rsd8106
 
Behcet s Disease, Case presentation
Behcet s Disease, Case presentationBehcet s Disease, Case presentation
Behcet s Disease, Case presentationGamal Agmy
 
Medicine (respiratory) treatment guidelines Govt of India
Medicine (respiratory) treatment guidelines Govt of IndiaMedicine (respiratory) treatment guidelines Govt of India
Medicine (respiratory) treatment guidelines Govt of IndiaDr Jitu Lal Meena
 
Acute Respiratory Distress Syndrome. ppt 2023 Siva P Sivakumar.pptx
Acute Respiratory Distress Syndrome. ppt 2023 Siva P Sivakumar.pptxAcute Respiratory Distress Syndrome. ppt 2023 Siva P Sivakumar.pptx
Acute Respiratory Distress Syndrome. ppt 2023 Siva P Sivakumar.pptxTamilaruviMuniraj
 
Acute respiratory distress syndrome 2018
Acute respiratory distress syndrome   2018Acute respiratory distress syndrome   2018
Acute respiratory distress syndrome 2018Lin Mann
 
Acute respiratory distress syndrome ARDS.pptx
Acute respiratory distress syndrome ARDS.pptxAcute respiratory distress syndrome ARDS.pptx
Acute respiratory distress syndrome ARDS.pptxssuser75a68f
 
1_Hypoxemic_Respiratory_Failure_Part_1_Basics_of_Hypoxemic_Respiratory.pdf
1_Hypoxemic_Respiratory_Failure_Part_1_Basics_of_Hypoxemic_Respiratory.pdf1_Hypoxemic_Respiratory_Failure_Part_1_Basics_of_Hypoxemic_Respiratory.pdf
1_Hypoxemic_Respiratory_Failure_Part_1_Basics_of_Hypoxemic_Respiratory.pdframbhoopal1
 
The Pathology of Acute Lung Injury
The Pathology of Acute Lung InjuryThe Pathology of Acute Lung Injury
The Pathology of Acute Lung InjuryDr. Anunoy Samanta
 

Similar a Updates on Acute respiratory distress syndrome (20)

Ards(En终)
Ards(En终)Ards(En终)
Ards(En终)
 
ACUTE RESPIRATORY DISTRESS SYNDROME
ACUTE RESPIRATORY DISTRESS SYNDROMEACUTE RESPIRATORY DISTRESS SYNDROME
ACUTE RESPIRATORY DISTRESS SYNDROME
 
Ards
ArdsArds
Ards
 
Ards level 3 lecture
Ards level 3 lectureArds level 3 lecture
Ards level 3 lecture
 
Ards azocar
Ards   azocarArds   azocar
Ards azocar
 
ARDS.pptx
ARDS.pptxARDS.pptx
ARDS.pptx
 
Dr. Radhey Shyam (presentation)
Dr. Radhey Shyam (presentation)Dr. Radhey Shyam (presentation)
Dr. Radhey Shyam (presentation)
 
ARDS
ARDSARDS
ARDS
 
ARDS
ARDSARDS
ARDS
 
ARDS
ARDS ARDS
ARDS
 
Behcet s Disease, Case presentation
Behcet s Disease, Case presentationBehcet s Disease, Case presentation
Behcet s Disease, Case presentation
 
Ards gray
Ards   grayArds   gray
Ards gray
 
Medicine (respiratory) treatment guidelines Govt of India
Medicine (respiratory) treatment guidelines Govt of IndiaMedicine (respiratory) treatment guidelines Govt of India
Medicine (respiratory) treatment guidelines Govt of India
 
Acute Respiratory Distress Syndrome. ppt 2023 Siva P Sivakumar.pptx
Acute Respiratory Distress Syndrome. ppt 2023 Siva P Sivakumar.pptxAcute Respiratory Distress Syndrome. ppt 2023 Siva P Sivakumar.pptx
Acute Respiratory Distress Syndrome. ppt 2023 Siva P Sivakumar.pptx
 
Acute respiratory distress syndrome 2018
Acute respiratory distress syndrome   2018Acute respiratory distress syndrome   2018
Acute respiratory distress syndrome 2018
 
Acute respiratory distress syndrome ARDS.pptx
Acute respiratory distress syndrome ARDS.pptxAcute respiratory distress syndrome ARDS.pptx
Acute respiratory distress syndrome ARDS.pptx
 
ARDS
ARDSARDS
ARDS
 
Acute respiratory distress syndrome
Acute respiratory distress syndromeAcute respiratory distress syndrome
Acute respiratory distress syndrome
 
1_Hypoxemic_Respiratory_Failure_Part_1_Basics_of_Hypoxemic_Respiratory.pdf
1_Hypoxemic_Respiratory_Failure_Part_1_Basics_of_Hypoxemic_Respiratory.pdf1_Hypoxemic_Respiratory_Failure_Part_1_Basics_of_Hypoxemic_Respiratory.pdf
1_Hypoxemic_Respiratory_Failure_Part_1_Basics_of_Hypoxemic_Respiratory.pdf
 
The Pathology of Acute Lung Injury
The Pathology of Acute Lung InjuryThe Pathology of Acute Lung Injury
The Pathology of Acute Lung Injury
 

Más de Hamdi Turkey

Practical approach to interstitial lung diseases
Practical approach to interstitial lung diseases Practical approach to interstitial lung diseases
Practical approach to interstitial lung diseases Hamdi Turkey
 
Pulmonary Tuberculosis
Pulmonary Tuberculosis Pulmonary Tuberculosis
Pulmonary Tuberculosis Hamdi Turkey
 
community acquired pneumonia (CAP)
community acquired pneumonia (CAP) community acquired pneumonia (CAP)
community acquired pneumonia (CAP) Hamdi Turkey
 
BASIC CONCEPTS IN LUNG DISEASE
BASIC CONCEPTS IN LUNG DISEASEBASIC CONCEPTS IN LUNG DISEASE
BASIC CONCEPTS IN LUNG DISEASEHamdi Turkey
 

Más de Hamdi Turkey (8)

Practical approach to interstitial lung diseases
Practical approach to interstitial lung diseases Practical approach to interstitial lung diseases
Practical approach to interstitial lung diseases
 
Pneumoconiosis
PneumoconiosisPneumoconiosis
Pneumoconiosis
 
Pulmonary Tuberculosis
Pulmonary Tuberculosis Pulmonary Tuberculosis
Pulmonary Tuberculosis
 
community acquired pneumonia (CAP)
community acquired pneumonia (CAP) community acquired pneumonia (CAP)
community acquired pneumonia (CAP)
 
BASIC CONCEPTS IN LUNG DISEASE
BASIC CONCEPTS IN LUNG DISEASEBASIC CONCEPTS IN LUNG DISEASE
BASIC CONCEPTS IN LUNG DISEASE
 
Bronchiectasis
BronchiectasisBronchiectasis
Bronchiectasis
 
COPD
COPDCOPD
COPD
 
Bronchial asthma
Bronchial asthmaBronchial asthma
Bronchial asthma
 

Último

POST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxPOST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxvirengeeta
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxDr.Nusrat Tariq
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformKweku Zurek
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...saminamagar
 
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsMedicoseAcademics
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxbkling
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?bkling
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 

Último (20)

POST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxPOST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptx
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptx
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy Platform
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
 
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes Functions
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptx
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 

Updates on Acute respiratory distress syndrome

  • 1. Updates on Acute respiratory distress syndrome Hamdi Turkey - chest physician
  • 2. I hope you are still awake at the end of this lecture !
  • 3. Case presentation A 35 year old male patient was r u s h e d i n t o t h e E R complaining of SOB for the past 3 days, he has fever, Tachypnea, pulse 110 bpm,BP 80/50 mmHg, pallor and cyanosed, normal JVP, normal S1 and S2 with no added sounds, on chest auscultation there was bilateral diffuse crackles. SpO2 on room air was 60, ABG : PaO2= 40, Pco2= 40, pH=7.3 What's the diagnosis?
  • 4. Learning Objectives To know the new definition of ARDS To understand the pathology and pathophysiology of ARDS To devise a ventilation strategy for these patients. To introduce the concept of ventilator induced lung injury To address adjunct and rescue therapy for patients with resistant hypoxemia.
  • 5. History I n 1 9 6 7 A s h b a u g h a n d colleagues published a case series in the Lancet which described a clinical syndrome, which they (later) termed “Adult R e s p i r a t o r y D i s t r e s s Syndrome” (ARDS). The 12 patients involved complained of acute respiratory distress, cyanosis refractory to oxygen t h e r a py, d e c r e a s e d l u n g c o m p l i a n c e a n d d i f f u s e pulmonary infiltrates on chest x-ray.
  • 6. Trauma doctors involved in treating victims of war had long been familiar with this syndrome, which came to be known as “wet lung”, “shock lung” or “Da-nang lung”. This problem had been identified during World War II but with the advent of advanced trauma (M.A.S.H. units during the Vietnam war) the prevalence of this form of respiratory failure was truly recognized. Over the past 30 or so years, this syndrome has come to be one of the central problems of intensive care: lung injury arising from a variety of different etiologies, each characterized by bilateral diffuse infiltrates on x-ray, hypoxemia, and non-cardiogenic pulmonary edema. History
  • 7. In 1988, an expanded definition was proposed that quantified the physiologic respiratory impairment through the use of a four-point lung- injury scoring system that was based on: level of positive end-expiratory pressure ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen static lung compliance degree of infiltration evident on chest radiographs. History
  • 8. Before research into the pathogenesis and treatment of this syndrome could proceed, it was necessary to formulate a clear definition of the syndrome. Such a definition was developed in 1994 by the American-European Consensus Conference (AECC) on acute respiratory distress syndrome (ARDS). The term “acute respiratory distress syndrome” was used instead of “adult respiratory distress syndrome” because the syndrome occurs in both adults and children. History
  • 9. The Berlin Definition of ARDS (published in 2012) has replaced the American-European Consensus Conference’s definition of ARDS (published in 1994). However, it should be recognized that most evidence is based upon prior definitions. History
  • 10. Other terms Shock lung Pump lung Traumatic wet lung Post traumatic atelectasis Adult hyaline membrane disease Progressive respiratory distress Acute respiratory insufficiency syndrome Haemorrhagic atelectasis Hypoxic hyperventilation Postperfusion lung Oxygen toxicity lung Wet lung White lung Transplant lung Da Nang lung Diffuse alveolar injury Acute diffuse lung injury Noncardiogenic pulmonary edema. Progressive pulmonary consolidation
  • 11. AECC Past definition of ARDS ARDS was defined as: the acute onset of respiratory failure, bilateral infiltrates on chest radiograph, hypoxemia as defined by a PaO2/FiO2 ratio ≤200 mmHg, and no evidence of left atrial hypertension or a pulmonary capillary pressure <18 mmHg (if measured) to rule out cardiogenic edema. In addition, Acute Lung Injury (ALI), the less severe form of acute respiratory failure, was different from ARDS only for the degree of hypoxemia, in fact it was defined by a 200 < PaO2/FiO2 ≤300 mmHg.
  • 12. The 1994 AECC definition became globally accepted, but had limitations The current definition is the ‘Berlin Definition’ published in 2013, which was created by a consensus panel of experts convened in 2011 (an initiative of the European Society of Intensive Care Medicine endorsed by the American Thoracic Society and the Society of Critical Care Medicine) AECC Past definition of ARDS
  • 13. ARDS BERLIN DEFINITION ARDS is an acute diffuse, inflammatory lung injury, leading to increased pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue… [ w i t h ] h y p o x e m i a a n d b i l a t e r a l radiographic opacities, associated with increased venous admixture, increased physiological dead space and decreased lung compliance.
  • 14. The goal of developing the Berlin definition was to try and improve feasibility, reliability, face and predictive validity ARDS BERLIN DEFINITION
  • 15. Timing of acute onset The timing of acute onset of respiratory failure to make diagnosis of ARDS is clearly defined in Berlin definition. It defines the exposure to a known risk factor or worsening of the respiratory symptoms within one week. It is important to identify risk factors that explain the context of acute respiratory failure arised from
  • 16. Oxygenation In the Berlin definition, there is no use of the term Acute Lung Injury (ALI). The committee felt that this term was used inappropriately in many contexts and hence was not helpful. In the Berlin definition, ARDS was classified as mild, moderate and severe according to the value of PaO2/FiO2 ratio. Importantly, the PaO2/FiO2 ratio value is considered only with a CPAP or PEEP value of at least 5 cmH2O.
  • 17. The chest radiograph is characterized by bilateral opacities involving at least 3 quadrants that are not fully explained by pleural effusions, atelectasis and nodules. In the absence of known risk factors, a cardiogenic origin of edema is to be excluded by objective evaluation of cardiac function with echocardiography. Consequently, the wedge pressure measurement was abandoned because ARDS may coexist with hydrostatic edema caused by fluid overload or cardiac failure. Chest X-ray
  • 18. Key components acute, meaning onset over 1 week or less bilateral opacities consistent with pulmonary edema must be present but may be detected on CT or chest radiograph PF ratio <300mmHg with a minimum of 5 cmH20 PEEP (or CPAP) must not be fully explained by cardiac failure or fluid overload,” in the physician’s best estimation using available information — an “objective assessment“ (e.g. echocardiogram) should be performed in most cases if there is no clear cause such as trauma or sepsis.
  • 19. Severity *on PEEP 5+; **observed in cohort ARDS is categorized as being mild, moderate, or severe: ARDS Severity PaO2/FiO2* Mortality** Mild 200 – 300 27% Moderate 100 – 200 32% Severe < 100 45%
  • 20. Changes from the 1994 AECC definition the term acute lung injury was abandoned measurement of the PaO2/FIO2 ratio was changed to require a specific minimum amount of PEEP 3 categories of ARDS were proposed (mild, moderate, and severe) based on the PaO2/FIO2 ratio Radiographic criteria were changed to improve interrater reliability PCWP criterion was removed and additional clarity was added to improve the ability to exclude cardiac causes of bilateral infiltrates
  • 22. Shortcoming of the AECC definition acute is ill defined PF ratio can be manipulated by adjusting PEEP CXR interpretation is unreliable PACs are rarely used PCWP may oscillate above and below the cut-off and may be elevated for reasons other than heart failure ALI was used inconsistently, just PF ratio 200 to 300, or all patients <300 including ARDS?
  • 23.
  • 24. Incidence and outcome ■ 20-75 per 100,000 ■ 30% mortality ■ Recovery may take 6-12 months ■ Residual: Restriction Obstruction Gas- Exchange Abnormalities Reduced Quality of Life
  • 25. Direct pneumonia aspiration of gastric contents lung contusion fat embolism Amniotic fluid embolism near drowning inhalational injury reperfusion injury non-pulmonary sepsis multiple trauma massive transfusion pancreatitits Salicylate or narcotic overdose cardiopulmonary bypass Indirect Risk factors
  • 26. Cardiogenic Vs non cardiogenic pulmonary edema Cardiogenic Non-Cardiogenic Patchy infiltrates in bases Effusions Kerley B lines Cardiomegaly Pulmonary vascular redistribution Excess fluid in alveoli Homogenous fluffy shadows No effusion No Kerley B lines No cardiomegaly No pulmonary vascular redistribution Protein, inflammatory cells, fluid
  • 29. Pathophysiology Classical phases Injury Exudative – alveolar capillary membrane disruption with inflammatory cell infiltrate and high protein exudate to form hyaline membranes Proliferative – proliferation of abnormal Type II alveoli cells and inflammatory cells Fibrotic – infiltration with fibroblasts which replace alveoli and alveolar ducts with fibrosis Resolution – slow and incomplete repair and restoration of architecture
  • 30.
  • 31. Pathophysiology Based on the histological appearance - Exudative phase (0-4 days) • Alveolar and interstitial edema • Capillary congestion • Destruction of type I alveolar cells • Early hyaline membrane formation Proliferative Phase (3-10 days) • Increased type II alveolar cells • Cellular infiltration of alveolar septum • Organisation of hyaline membranes Fibrotic Phase (>10 days) • Fibrosis of hyaline membranes and alveolar septum • Alveolar duct fibrosis
  • 32. Findings on Light Microscopy and Electron Microscopy during the Acute Phase (Panels A and D) and the Fibrosing- Alveolitis Phase (Panels B, C, and E) of Acute Respiratory Distress Syndrome.
  • 33. Pathophysiology Mechanisms in early phase - • Release of inflammatory cytokines – TNF alpha, IL- 1,6,8 • Failure of alveolar edema clearance, epithelial and endothelial damage • Increased permeability of alveolo – capillary membrane • Neutrophil migration and oxidative stress • Procoagulant shift – fibrin deposition • Surfactant dysfunction Mechanism in late (repair) phase – • Fibroproliferation -TGF beta, MMPs, thombospondin, plasmin, ROS • Remodelling - matrix and cell surface proteoglycans, MMP, imbalance of coagulation and fibrinolysis.
  • 35. Complex interplay pulmonary oedema from damage to the alveolocapillary barrier inflammatory infiltrates surfactant dysfunction It is essential to understand that although ALI is a diffuse process, it is also a heterogeneous process, and not all lung units are affected equally: normal and diseased tissue may exist side-by-side.
  • 36. Effects hypoxaemia (V/Q mismatch, impaired hypoxic pulmonar y vasoconstriction) increase in dependent densities (surfactant dysfunction, alveolar instabilities) decreased compliance (surfactant dysfunction, decreased lung volume, fibrosis) collapse/consolidation (increased compression of dependent lung) increased minute ventilation (increased in alveolar dead space) increased work of breathing (increased elastance, increased minute volume requirement) pulmonary hypertension (vasoconstriction, microvascular thrombi, fibrosis, PEEP)
  • 37. Host factors increasing the risk of ARDS Clinical variables found to be associated with an increased risk of ARDS Diabetes mellitus decreases the risk of ALI. chronic alcohol abuse hypoproteinemia advanced age, increased severity,and extent of injury or illness as measured by injury severity score (ISS) or APACHEscore hyper-transfusion of blood products cigarette smoking.
  • 38. Causative factors in ARDS Primary injury Host response Consequences of therapy
  • 40. Symptoms Acute respiratory distress syndrome (ARDS) is characterized by the development of acute dyspnea and hypoxemia within hours to days of an inciting event, such as trauma, sepsis, drug overdose, massive transfusion, acute pancreatitis, or aspiration. In many cases, the inciting event is obvious, but, in others (eg, drug overdose), it may be harder to identify. Patients developing ARDS are critically ill, often with multisystem organ failure, and they may not be capable of providing historical information. Typically, the illness develops within 12-48 hours after the inciting event, although, in rare instances, it may take up to a few days. With the onset of lung injury, patients initially note dyspnea with exertion. This rapidly progresses to severe dyspnea at rest, tachypnea, anxiety, agitation, and the need for increasingly high concentrations of inspired oxygen.
  • 41. Physical findings Physical findings often are nonspecific and include tachypnea, tachycardia, and the need for a high fraction of inspired oxygen (FIO2) to maintain oxygen saturation. The patient may be febrile or hypothermic. Because ARDS often occurs in the context of sepsis, associated hypotension and peripheral vasoconstriction with cold extremities may be present. Cyanosis of the lips and nail beds may occur. Examination of the lungs may reveal bilateral rales. Rales may not be present despite widespread involvement. Because the patient is often intubated and mechanically ventilated, decreased breath sounds over 1 lung may indicate a pneumothorax or endotracheal tube down the right main bronchus. Manifestations of the underlying cause (eg, acute abdominal findings in the case of ARDS caused by pancreatitis) are present.
  • 43. Laboratory investigations Routine blood counts RFT LFT Blood culture BNP ABG BAL ECHO Chest CT scan PCWP
  • 44. Classic Chest X Ray of a patient with ARDS, although the lung injury appears diffuse, when you look at the CT scan of the same patient on the right you can see that the lower lobes are densely consolidated and the upper lobes relatively spared. Nevertheless, this patient was severely hypoxic, and responded well to prone positioning.
  • 46. Therapy- goals Treatment of the underlying cause Cardio-pulmonary support Specific therapy targeted at lung therapy Supportive therapy
  • 47. Diagnosis and appropriate treatment of the underlying cause to minimise physiological impact of cause (drain collection, antibiotics, resuscitate, splint fractures) Nutritional support Standard ICU prophylaxis Stress ulcer prophylaxis Prevention of nosocomial infections CVP monitoring with CV line with appropriate fluid therapy General measures
  • 48. Goal of management of a patient with ARDS
  • 50. Lung protective strategy in ARDS A myth or a fact!
  • 52. Therapy- mechanical ventilation The Problem: Ventilator- Induced Lung Injury ■ High volumes and pressures: Stress ( barotrauma) ■ Overdistension & Alveolar Cracking ( volumtrauma) ■ Cyclic Opening and closing of atelectatic alveoli ( atelectrauma) Cause increased permeability and alveolar damage
  • 53. The Problem: Oxygen Toxicity ■ Free Radicals ■ Oxygen Washout and De-Recruitment High FiO2 can lead to further alveolar damage Therapy- mechanical ventilation
  • 54. ■ Intubation almost always necessary ■ In past, goal was to normalize pH, PaCO2, PaO2 ■ High volumes and pressures were used ■ Worse outcomes Therapy- mechanical ventilation
  • 55. Lung protective strategy Amato et al. 1998, Effects of a protective- ventilation strategy on mortality in the acute respiratory distress syndrome. N. Engl. J. Med. 338:347-54 ■ 53 pts with early ARDS ■ Compared “conventional” ventilation of 12ml/kg to “protective” 6ml/kg ■ Low PEEP. PaCO2 35-38 ■ Improved survival at 28 days ■ Higher percentage of ventilator weaning ■ Less barotrauma
  • 56. The Acute Respiratory Distress Network. 2000. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N. Engl. J. Med. 342:1301-8 ■ Larger Trial. 861 patients ■ Compared 12 ml/kg vs. 6ml/kg ventilation. ■ Plateau pressures 50 cm H2O vs. 30 cm H2O. ■ Trial ended early: ■39.8% mortality vs. 31% mortality THIS HAS CHANGED CLINICAL PRACTICE Lung protective strategy
  • 57. Mechanical ventilation ARDS Network protective lung ventilation strategy (from the ARMA study) controlled ventilation TV 6mL/kg avoid overstretch (volutrauma) and inadequate recruitment (atelectrauma) PEEP 5-15 Plateau pressure <30 cmH20 (higher than this contributes to VILI from overstretching and hyperinflation of the functional ‘baby lung’)
  • 58. mode of ventilation: generally no difference PCV tends to be used c/o plateau pressure approximates peak pressure, with VC plateau pressure needs to be measured no role for inverse ratio ventilation (I:E ratio > 1) -> increased mean airway pressure + haemodynamic instability + regional hyperinflation oxygenation target: SpO2 88-95%, PaO2 > 55-80 mmHg carbon dioxide target: ARDSnet aimed for a normal CO2 -> but lung is exposed to repeated tidal stretch, ideally hypercapnia should be minimised but there isn’t compelling data to suggest it is harmful unless there is an obvious reason (raised ICP, pregnancy).
  • 62.
  • 63. Other techniques to improve oxygenation prone posture: improves oxygenation and mortality in severe ARDS recruitment manoeuvres (e.g. PEEP 30-40cmH2O held for 30 seconds or staircase recruitment manouvre) -> can improve oxygenation but controversial, not everyone responds inhaled iNO: optimisation of V/Q mismatch, 1-60ppm, on 40-70% will respond, monitor for metHb inhaled prostacycline (PGI2): optimisation of V/Q mis-match, 1-50ng/kg/min, as effective as iNO
  • 64. Pharmacological therapy surfactant replacement therapy: theoretically good, improves oxygenation but no improvement in mortality, problems with distribution to alveoli Diuretics : liberal vs conservative strategy glucocorticoids: improvement in ventilator free days and shock, no improvement in mortality and increase in weakness ketoconazole: antifungal that inhibits thromboxane synthase and 5-lipooxygenase -> early data but not confirmed. others: cytokine antagonism, NSAIDS, scavengers of O2 radicals, lisofylline -> no success Seek and treat underlying causes and complications
  • 65. A randomized, clinical trial determined that simvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, improved oxygenation and respiratory mechanics in patients with ALI. Further studies are needed, but treatment with simvastatin appears safe and may be associated with improved organ dysfunction in patients with ALI. Statins Pharmacological therapy Activated protein C Drotrecogin alfa was withdrawn from the worldwide market October 25, 2011. In the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS)-SHOCK clinical trial, drotrecogin alfa failed to demonstrate a statistically significant reduction in 28-day all-cause mortality in patients with severe sepsis and septic shock. Trial results observed a 28-day all-cause mortality rate of 26.4% in patients treated with activated drotrecogin alfa compared with 24.2% in the placebo group of the study.
  • 66. In these critically ill patients, pay careful attention to early recognition of potential complications in the intensive care unit (ICU), including pneumothorax, IV line infections, skin breakdown, inadequate nutrition, arterial occlusion at the site of intra-arterial monitoring devices, DVT and pulmonary embolism (PE), retroperitoneal hemorrhage, gastrointestinal (GI) hemorrhage, erroneous placement of lines and tubes, and the development of muscle weakness.
  • 67. Prognosis pulmonary function returns to normal at 6-12 months in survivors occasionally patient have severe restrictive lung disease although this is the case, many patient have a severe reduction and pulmonary QOL -> depression, anxiety and PTSD are common patient often have cognitive impairment -> these correlate with the period and severity of hypoxia
  • 68.
  • 69.